Click here to close now.

Welcome!

News Feed Item

Multiple Sclerosis Global Clinical Trials Review, H2, 2014

NEW YORK, Aug. 5, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Multiple Sclerosis Global Clinical Trials Review, H2, 2014

http://www.reportlinker.com/p02256139/Multiple-Sclerosis-Global-Clinical-Trials-Review-H2-2014.html

Multiple Sclerosis Global Clinical Trials Review, H2, 2014

Summary

GlobalData's clinical trial report, "Multiple Sclerosis Global Clinical Trials Review, H2, 2014" provides data on the Multiple Sclerosis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Multiple Sclerosis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Multiple Sclerosis. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Multiple Sclerosis 6
Report Guidance 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10

Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Five Countries Contributing to Clinical Trials in Middle East and Africa 13
Top Five Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by G7 Countries: Proportion of Multiple Sclerosis to Central Nervous System Clinical Trials 15
Clinical Trials by Phase in G7 Countries 16
Clinical Trials in G7 Countries by Trial Status 17
Clinical Trials by E7 Countries: Proportion of Multiple Sclerosis to Central Nervous System Clinical Trials 18
Clinical Trials by Phase in E7 Countries 19
Clinical Trials in E7 Countries by Trial Status 20
Clinical Trials by Phase 21
In Progress Trials by Phase 22
Clinical Trials by Trial Status 23
Clinical Trials by End Point Status 24
Unaccomplished Trials of Multiple Sclerosis 25
Subjects Recruited Over a Period of Time 35
Clinical Trials by Sponsor Type 36

Prominent Sponsors 37
Top Companies Participating in Multiple Sclerosis Therapeutics Clinical Trials 38
Prominent Drugs 40
Latest Clinical Trials News on Multiple Sclerosis 41
Jun 16, 2014: Biogen Idec and AbbVie Announce Positive Top-Line Results from Phase 3 Study Investigating Daclizumab High-Yield Process in Multiple Sclerosis 41
May 27, 2014: Bionure MS Drug Candidate Shows Positive Results for Myelin Repair in Cell Culture Assay 41
Clinical Trial Profiles 43
Clinical Trial Overview of Top Companies 43
Biogen Idec Inc. 43
Clinical Trial Overview of Biogen Idec Inc. 43
E. Merck KG 53
Clinical Trial Overview of E. Merck KG 53
Novartis AG 59
Clinical Trial Overview of Novartis AG 59
Teva Pharmaceutical Industries Limited 64
Clinical Trial Overview of Teva Pharmaceutical Industries Limited 64
Bayer AG 68
Clinical Trial Overview of Bayer AG 68

Sanofi 72
Clinical Trial Overview of Sanofi 72
GlaxoSmithKline plc 75
Clinical Trial Overview of GlaxoSmithKline plc 75
Acorda Therapeutics, Inc. 77
Clinical Trial Overview of Acorda Therapeutics, Inc. 77
Elan Corporation, plc 79
Clinical Trial Overview of Elan Corporation, plc 79
Pfizer Inc. 80
Clinical Trial Overview of Pfizer Inc. 80
Clinical Trial Overview of Top Institutes / Government 81
National Institute of Neurological Disorders and Stroke 81
Clinical Trial Overview of National Institute of Neurological Disorders and Stroke 81
Charite - Universitatsmedizin Berlin 83
Clinical Trial Overview of Charite - Universitatsmedizin Berlin 83
Tehran University of Medical Sciences 84
Clinical Trial Overview of Tehran University of Medical Sciences 84
U.S. Department of Veterans Affairs 85
Clinical Trial Overview of U.S. Department of Veterans Affairs 85
Oregon Health & Science University 86
Clinical Trial Overview of Oregon Health & Science University 86
The National Institute of Allergy and Infectious Diseases 87

Clinical Trial Overview of The National Institute of Allergy and Infectious Diseases 87
University of Washington 88
Clinical Trial Overview of University of Washington 88
St. Andrea Hospital Sapienza Rome University 89
Clinical Trial Overview of St. Andrea Hospital Sapienza Rome University 89
Imperial College London 90
Clinical Trial Overview of Imperial College London 90
Department of Health, UK 91
Clinical Trial Overview of Department of Health, UK 91
Five Key Clinical Profiles 92
Appendix 196
Abbreviations 196
Definitions 196
Research Methodology 197
Secondary Research 197
About GlobalData 198
Contact Us 198
Disclaimer 198
Source 198

List of Tables

Multiple Sclerosis Therapeutics, Global, Clinical Trials by Region, 2014* 7
Multiple Sclerosis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Multiple Sclerosis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Multiple Sclerosis Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2014* 10
Multiple Sclerosis Therapeutics Clinical Trials, Europe, Top Five Countries, 2014* 11
Multiple Sclerosis Therapeutics Clinical Trials, North America, Top Countries, 2014* 12
Multiple Sclerosis Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2014* 13
Multiple Sclerosis Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2014* 14
Proportion of Multiple Sclerosis to Central Nervous System Clinical Trials, G7 Countries (%), 2014* 15
Multiple Sclerosis Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Multiple Sclerosis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Multiple Sclerosis to Central Nervous System Clinical Trials, E7 Countries (%), 2014* 18
Multiple Sclerosis Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Multiple Sclerosis Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 20
Multiple Sclerosis Therapeutics, Global, Clinical Trials by Phase, 2014* 21

Multiple Sclerosis Therapeutics, Global, Clinical Trials In Progress by Phase 2014* 22
Multiple Sclerosis Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
Multiple Sclerosis Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24
Multiple Sclerosis Therapeutics, Global, Suspended Clinical Trials, 2014* 25
Multiple Sclerosis Therapeutics, Global, Withdrawn Clinical Trials, 2014* 26
Multiple Sclerosis Therapeutics, Global, Terminated Clinical Trials, 2014* 28
Multiple Sclerosis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 35
Multiple Sclerosis Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014* 36
Multiple Sclerosis Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 37
Multiple Sclerosis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 39
Multiple Sclerosis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 40
Multiple Sclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Biogen Idec Inc., 2014* 43
Multiple Sclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by E. Merck KG, 2014* 53
Multiple Sclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Novartis AG, 2014* 59

Multiple Sclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Teva Pharmaceutical Industries Limited, 2014* 64
Multiple Sclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Bayer AG, 2014* 68
Multiple Sclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Sanofi, 2014* 72
Multiple Sclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by GlaxoSmithKline plc, 2014* 75
Multiple Sclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Acorda Therapeutics, Inc., 2014* 77
Multiple Sclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Elan Corporation, plc, 2014* 79
Multiple Sclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Pfizer Inc., 2014* 80
Multiple Sclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by National Institute of Neurological Disorders and Stroke, 2014* 81
Multiple Sclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Charite - Universitatsmedizin Berlin, 2014* 83
Multiple Sclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Tehran University of Medical Sciences, 2014* 84
Multiple Sclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by U.S. Department of Veterans Affairs, 2014* 85

Multiple Sclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Oregon Health & Science University, 2014* 86
Multiple Sclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by The National Institute of Allergy and Infectious Diseases, 2014* 87
Multiple Sclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Washington, 2014* 88
Multiple Sclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by St. Andrea Hospital Sapienza Rome University, 2014* 89
Multiple Sclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Imperial College London, 2014* 90
Multiple Sclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Department of Health, UK, 2014* 91

List of Figures

Multiple Sclerosis Therapeutics, Global, Clinical Trials by Region (%), 2014* 7
Multiple Sclerosis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Multiple Sclerosis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Multiple Sclerosis Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2014* 10
Multiple Sclerosis Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014* 11
Multiple Sclerosis Therapeutics Clinical Trials, North America, Top Countries (%), 2014* 12
Multiple Sclerosis Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2014* 13
Multiple Sclerosis Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2014* 14
Proportion of Multiple Sclerosis to Central Nervous System Clinical Trials, G7 Countries (%), 2014* 15
Multiple Sclerosis Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Multiple Sclerosis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Multiple Sclerosis to Central Nervous System Clinical Trials, E7 Countries (%), 2014* 18

Multiple Sclerosis Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Multiple Sclerosis Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 20
Multiple Sclerosis Therapeutics, Global, Clinical Trials by Phase (%), 2014* 21
Multiple Sclerosis Therapeutics, Global, Clinical Trials In Progress by Phase, 2014* 22
Multiple Sclerosis Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
Multiple Sclerosis Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24
Multiple Sclerosis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 35
Multiple Sclerosis Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014* 36
Multiple Sclerosis Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 37
Multiple Sclerosis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 38
Multiple Sclerosis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 40
GlobalData Methodology 197

To order this report: Multiple Sclerosis Global Clinical Trials Review, H2, 2014
http://www.reportlinker.com/p02256139/Multiple-Sclerosis-Global-Clinical-Trials-Review-H2-2014.html

_________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001

SOURCE Reportlinker

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
Overgrown applications have given way to modular applications, driven by the need to break larger problems into smaller problems. Similarly large monolithic development processes have been forced to be broken into smaller agile development cycles. Looking at trends in software development, microservices architectures meet the same demands. Additional benefits of microservices architectures are compartmentalization and a limited impact of service failure versus a complete software malfunction. ...
"We help to transform an organization and their operations and make them more efficient, more agile, and more nimble to move into the cloud or to move between cloud providers and create an agnostic tool set," noted Jeremy Steinert, DevOps Services Practice Lead at WSM International, in this SYS-CON.tv interview at @DevOpsSummit, held June 9-11, 2015, at the Javits Center in New York City.
The basic integration architecture, as defined by ESBs, hasn’t changed for more than a decade. Most cloud integration providers still rely on an ESB architecture and their proprietary connectors. As a result, enterprise integration projects suffer from constraints of availability and reliability of these connectors that are not re-usable across other integration vendors. However, the rapid adoption of APIs and almost ubiquitous availability of APIs amongst most SaaS and Cloud applications are ra...
Agile, which started in the development organization, has gradually expanded into other areas downstream - namely IT and Operations. Teams – then teams of teams – have streamlined processes, improved feedback loops and driven a much faster pace into IT departments which have had profound effects on the entire organization. In his session at DevOps Summit, Anders Wallgren, Chief Technology Officer of Electric Cloud, will discuss how DevOps and Continuous Delivery have emerged to help connect dev...
"What Dyn is able to do with our Internet performance and our Internet intelligence is give companies visibility into what is actually going on in that cloud," noted Corey Hamilton, Product Marketing Manager at Dyn, in this SYS-CON.tv interview at 16th Cloud Expo, held June 9-11, 2015, at the Javits Center in New York City.
The Internet of Things is not only adding billions of sensors and billions of terabytes to the Internet. It is also forcing a fundamental change in the way we envision Information Technology. For the first time, more data is being created by devices at the edge of the Internet rather than from centralized systems. What does this mean for today's IT professional? In this Power Panel at @ThingsExpo, moderated by Conference Chair Roger Strukhoff, panelists addressed this very serious issue of pro...
Internet of Things is moving from being a hype to a reality. Experts estimate that internet connected cars will grow to 152 million, while over 100 million internet connected wireless light bulbs and lamps will be operational by 2020. These and many other intriguing statistics highlight the importance of Internet powered devices and how market penetration is going to multiply many times over in the next few years.
Manufacturing has widely adopted standardized and automated processes to create designs, build them, and maintain them through their life cycle. However, many modern manufacturing systems go beyond mechanized workflows to introduce empowered workers, flexible collaboration, and rapid iteration. Such behaviors also characterize open source software development and are at the heart of DevOps culture, processes, and tooling.
Today air travel is a minefield of delays, hassles and customer disappointment. Airlines struggle to revitalize the experience. GE and M2Mi will demonstrate practical examples of how IoT solutions are helping airlines bring back personalization, reduce trip time and improve reliability. In their session at @ThingsExpo, Shyam Varan Nath, Principal Architect with GE, and Dr. Sarah Cooper, M2Mi’s VP Business Development and Engineering, will explore the IoT cloud-based platform technologies drivi...
Containers have changed the mind of IT in DevOps. They enable developers to work with dev, test, stage and production environments identically. Containers provide the right abstraction for microservices and many cloud platforms have integrated them into deployment pipelines. DevOps and Containers together help companies to achieve their business goals faster and more effectively. In his session at DevOps Summit, Ruslan Synytsky, CEO and Co-founder of Jelastic, reviewed the current landscape of...
Live Webinar with 451 Research Analyst Peter Christy. Join us on Wednesday July 22, 2015, at 10 am PT / 1 pm ET In a world where users are on the Internet and the applications are in the cloud, how do you maintain your historic SLA with your users? Peter Christy, Research Director, Networks at 451 Research, will discuss this new network paradigm, one in which there is no LAN and no WAN, and discuss what users and network administrators gain and give up when migrating to the agile world of clo...
SYS-CON Events announced today that JFrog, maker of Artifactory, the popular Binary Repository Manager, will exhibit at SYS-CON's @DevOpsSummit Silicon Valley, which will take place on November 3–5, 2015, at the Santa Clara Convention Center in Santa Clara, CA. Based in California, Israel and France, founded by longtime field-experts, JFrog, creator of Artifactory and Bintray, has provided the market with the first Binary Repository solution and a software distribution social platform.
"We got started as search consultants. On the services side of the business we have help organizations save time and save money when they hit issues that everyone more or less hits when their data grows," noted Otis Gospodnetić, Founder of Sematext, in this SYS-CON.tv interview at @DevOpsSummit, held June 9-11, 2015, at the Javits Center in New York City.
Internet of Things (IoT) will be a hybrid ecosystem of diverse devices and sensors collaborating with operational and enterprise systems to create the next big application. In their session at @ThingsExpo, Bramh Gupta, founder and CEO of robomq.io, and Fred Yatzeck, principal architect leading product development at robomq.io, discussed how choosing the right middleware and integration strategy from the get-go will enable IoT solution developers to adapt and grow with the industry, while at th...
Containers are revolutionizing the way we deploy and maintain our infrastructures, but monitoring and troubleshooting in a containerized environment can still be painful and impractical. Understanding even basic resource usage is difficult – let alone tracking network connections or malicious activity. In his session at DevOps Summit, Gianluca Borello, Sr. Software Engineer at Sysdig, will cover the current state of the art for container monitoring and visibility, including pros / cons and liv...